The UK’s National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) as a combination therapy for untreated multiple myeloma. NICE recommended the therapy, developed by Johnson & Johnson, with bortezomib, lenalidomide and dexamethasone (D-VRd) for untreated multiple myeloma in adults when an autologous stem cell transplant (ASCT) is unsuitable. The recommendation is based on data from a […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!